Research Analysts Issue Forecasts for USNA Q3 Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Research analysts at Sidoti Csr upped their Q3 2026 EPS estimates for shares of USANA Health Sciences in a report released on Thursday, January 15th. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $0.54 for the quarter, up from their previous estimate of $0.50. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2026 earnings at $0.58 EPS and FY2026 earnings at $1.95 EPS.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.47 by ($0.62). USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.97%. The business had revenue of $213.67 million during the quarter, compared to analyst estimates of $224.97 million.

USNA has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a research note on Monday, December 29th. Zacks Research lowered USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 7th. Finally, Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Two equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $36.00.

USANA Health Sciences Stock Performance

Shares of USANA Health Sciences stock opened at $22.01 on Monday. The firm has a fifty day moving average of $19.96 and a two-hundred day moving average of $25.07. The stock has a market capitalization of $402.40 million, a price-to-earnings ratio of 25.02, a PEG ratio of 0.94 and a beta of 0.65. USANA Health Sciences has a 52 week low of $18.48 and a 52 week high of $38.32.

Institutional Investors Weigh In On USANA Health Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Pzena Investment Management LLC raised its stake in shares of USANA Health Sciences by 1.2% in the 3rd quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company’s stock valued at $33,407,000 after purchasing an additional 14,328 shares during the period. Vanguard Group Inc. grew its holdings in shares of USANA Health Sciences by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock worth $29,452,000 after buying an additional 57,249 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of USANA Health Sciences by 1.9% during the third quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock worth $25,210,000 after buying an additional 17,318 shares in the last quarter. Two Sigma Investments LP raised its position in USANA Health Sciences by 349.8% in the 3rd quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock valued at $4,434,000 after buying an additional 125,158 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in USANA Health Sciences by 64.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 150,090 shares of the company’s stock valued at $4,582,000 after acquiring an additional 58,921 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Frederic J. Winssinger sold 2,000 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $19.21, for a total transaction of $38,420.00. Following the sale, the director owned 5,986 shares of the company’s stock, valued at $114,991.06. This trade represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director John Turman Fleming sold 1,750 shares of the business’s stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $19.79, for a total value of $34,632.50. Following the completion of the transaction, the director owned 4,565 shares of the company’s stock, valued at $90,341.35. This represents a 27.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 5,680 shares of company stock valued at $114,090 over the last 90 days. Corporate insiders own 0.63% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.